Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: The V-HeFT paradox

Clinical Pharmacokinetics

Volumn 46, Issue 10, 2007, Pages 885-895

  Tam, S William ^a   Sabolinski, Michael L ^a   Worcel, Manuel ^a   Packer, Milton ^b   Cohn, Jay N ^c  

^a NitroMed Inc   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ISOSORBIDE DINITRATE;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; DOSAGE FORMS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; MALE; TABLETS; THERAPEUTIC EQUIVALENCY; VASODILATOR AGENTS;

EID: 34548823820     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746100-00006     Document Type: Article

References (26)

1. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study. N Engl J Med 1986; 314: 1547-52
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
5. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843-8
6. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-8
7. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosor-bide dinitrate and hydralazine in Blacks with heart failure. N Engl J Med 2004; 351: 2049-57
8. Data on file, NitroMed, Inc., 1999
9. Center for Drug Evaluation and Research, US FDA. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. Revision 1 [online]. Rockville (MD): Center for Drug Evaluation and Research, 2003 Mar. Available from URL: http://www.fda.gov/cder/ guidance/5356fnl.pdf [Accessed 2007 Sep 5]
10. Relling MV. Polymorphic drug metabolism. Clin Pharm 1989; 8: 852-63
11. Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 1991; 20: 429-46
12. Reidenberg MM, Drayer D, de Marco AL, et al. Hydralazine elimination in man. Clin Pharmacol Ther 1973; 14: 970-7
13. Shepherd AMM, Irving NA, Ludden TM, et al. Effect of oral dose size on hydralazine kinetics and vasodepressor response. Clin Pharmacol Ther 1984; 36: 595-600
14. Crawford MH, Ludden TM, Kennedy GT. Determinants of systemic availability of oral hydralazine in heart failure. Clin Pharmacol Ther 1985; 38: 538-43
15. Ludden TM, Rotenberg KS, Ludden LK, et al. Relative bioavailability of immediate and sustained-release of hydralazine formulations. J Pharm Sci 1988; 7: 1026-32
16. Fung HL, McNiff EF, Ruggirello D, et al. Kinetics of isosorbide dinitrate and relationships to pharmacological effects. Br J Clin Pharmacol 1981; 11: 579-90
17. Franciosa JA, Weber KT, Levine TB, et al. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J 1982; 104: 587-94
18. Mulrow CD, Mulrow JP, Linn WD, et al. Relative efficacy of vasodilator therapy in chronic congestive heart failure: implications of randomized trials. JAMA 1988; 259: 3422-6
19. Kanamasa K, Hayashi T, Takenaka T, et al. Continuous long-term dosing with oral slow-release isosorbide dinitrate does not reduce incidence of cardiac events in patients with healed myocardial infarction. Clin Cardiol 2001; 24: 608-14
20. Kanamasa K, Hayashi T, Kimura A, et al. Long-term, continuous treatment with both oral and transdermal nitrates increase cardiac events in healed myocardial infarction patients. Angiology 2002; 53: 399-408
21. Rauhala P, Chiueh CC. Effects of atypical antioxidative agents, S-nitrosoglutathione and manganese, on brain lipid peroxidation induced by iron leaking from tissue disruption. Annals N Y Acad Sci 2000; 899: 238-54
22. Münzel T, Kurz J, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest 1996; 98: 1465-70
23. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med 2004; 351: 2112-4
24. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991; 84: 35-9
25. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995; 26: 1575-80
26. Elkayam U. Prevention of nitrate tolerance with concomitant administration of hydralazine. Can J Cardiol 1996; 12 Suppl. C: 17C-21C